MTOR and type 2 diabetes mellitus: Cardiometabolic diseases, including hyper-tension, obesity, type 2 diabetes, and dyslipidemia, share common molecular pathways, and mammalian target of rapamycin (mTOR) is a pharmacological target for improving metabolic and cardiovascular outcomes.